Shop

The Hay Group Singapore on Pharma deals don’t have to threaten innovation

eBook (PDF), 1 Pages
This item has not been rated yet
Price: $8.99
In pharma, the big story of the spring and summer has been M&A. The drama began in April with an asset swap between GSK and Novartis. The most recent headline grabbers have been inversion deals like AbbVie’s $54 billion acquisition of Shire. All this deal activity is a potential threat to innovation. Why? During a deal, it’s easy to overlook the intangible drivers of development: people and culture. Deal mania makes it easy to forget that people and the way they work together are the main drivers of innovation. Drug development is a team sport, and the way the players interact is a major factor in achieving success. Too often, deals break up environments that have made innovation possible.
Available in PDF Format

Ratings & Reviews

Log in to review this item
There are no reviews for the current version of this product
Refreshing...
There are no reviews for previous versions of this product
Refreshing...

Product Details

ISBN
9781365363870
Edition
1st Edition
Published
August 30, 2016
Language
English
Pages
1
File Format
PDF
File Size
48 KB

Formats for this Ebook

PDF
Required Software Any PDF Reader, Apple Preview
Supported Devices Windows PC/PocketPC, Mac OS, Linux OS, Apple iPhone/iPod Touch... (See More)
# of Devices Unlimited
Flowing Text / Pages Pages
Printable? Yes
Report This Content to Lulu >

Moderation of Questionable Content

Thank you for your interest in helping us moderate questionable content on Lulu. If you need assistance with an order or the publishing process, please contact our support team directly.

How does this content violate the Lulu Membership Agreement?

Keywords

Listed In

More From Amanda Bin